Uniting biological toolkits for a new approach to ALS

Google DeepMind Blog Tools

Summary

DeepMind's Co-Scientist AI tool bridges the expertise of two researchers from different biological fields to accelerate ALS research by generating testable hypotheses and identifying RNA-based mechanisms for potential therapies.

Co-Scientist unites Boston Children’s Hospital and MIT’s labs to explore new RNA-based treatments for ALS.
Original Article
View Cached Full Text

Cached at: 05/19/26, 07:16 PM

# Uniting biological toolkits for a new approach to ALS Source: [https://deepmind.google/blog/uniting-biological-toolkits-for-a-new-approach-to-als/](https://deepmind.google/blog/uniting-biological-toolkits-for-a-new-approach-to-als/) Ritu Raman at MIT and Ryan Flynn at Boston Children's Hospital approach human biology with very different toolkits, but Co\-Scientist is bridging their labs\. Raman, a mechanical engineer, builds living nerve and muscle tissues to model diseases that affect voluntary movement\. Her husband Flynn, a chemical biologist, maps RNA on the surface of cells to see how it influences cellular communication and how pathogens invade\. When Raman decided to investigate ALS, which was outside of her usual domain, she faced a sprawling, contradictory literature that would usually take months to grasp\. Co\-Scientist compressed that work, quickly helping Raman interrogate the evidence in relation to her tissue model, turn ideas into testable hypotheses, and rank potential directions in accordance with the trade\-offs labs actually face, such as feasibility and potential risk–reward\. But Co\-Scientist’s best leads came with a catch: they involved what happens at the surface of cells, where much of their communication is mediated\. Raman could manipulate tissues and measure outcomes, but decoding the molecular interactions driving those signals was outside her area of expertise\. That gap became the catalyst for collaboration\. Raman brought her new research directions to Flynn, and the pair used Co\-Scientist iteratively, combining its best ideas into creative research pathways that united their distinct toolkits\. To develop new therapies, their hunt is now on for novel RNA\-based mechanisms—and potentially RNA\-based drugs—that could be used to target ALS\.

Similar Articles

Accelerating discovery of liver disease mechanisms

Google DeepMind Blog

DeepMind's Co-Scientist AI system helped researchers at the University of Edinburgh generate a novel, experimentally verified hypothesis linking the NLRP3 inflammasome to the mechanism of drug resmetirom in MASH liver disease, potentially enabling targeted combination therapies.

Opening new paths in aging research

Google DeepMind Blog

Calico Life Sciences uses Google DeepMind's Co‑Scientist to connect scattered findings in aging biology and generate testable hypotheses, such as a novel hypothesis about ISR regulation by metabolism.

Finding the molecular switches behind new infectious diseases

Google DeepMind Blog

Professor Clare Bryant at the University of Cambridge is using DeepMind's Co-Scientist to rapidly identify molecular switches that cause severe diseases like sepsis when pathogens jump between species, cutting research time from years to months.